Abstract mRNA-based drugs have tremendous potential as clinical treatments, however, a
major challenge in realizing this drug class will promise to develop methods for safely …

RNA medicines represent a paradigm shift in treatment and prevention of critical diseases of
global significance, eg, infectious diseases. The highly successful messenger RNA (mRNA) …

The present use of mRNA vaccines against COVID-19 has shown for the first time the
potential of mRNA vaccines for infectious diseases. Here we will summarize the current …

Chikungunya virus (CHIKV), a single-stranded RNA virus transmitted by Aedes mosquitoes,
poses a significant global health threat, with severe complications observed in vulnerable …

The co-delivery of microRNAs (miRNAs) and protein-coding RNA presents an opportunity
for a combined approach to gene expression and gene regulation for therapeutic …

The first vaccine against chikungunya virus (CHIKV) was recently licensed in the US,
Europe, and Canada (brand IXCHIQ®, referred to as VLA1553). Other pathogenic …

Chikungunya virus (CHIKV) is an arthropod-borne alphavirus which infects people severely
and is responsible for epidemic outbreaks worldwide. Despite its rising prevalence globally …

mRNA was discovered in 1961, but it was not used as a vaccine until after three decades.
Recently, the development of mRNA vaccine technology gained great impetus from the …

Messenger RNA (mRNA) is a type of RNA that carries genetic information from DNA to the
ribosome, where it is translated into proteins. mRNA has emerged as a powerful platform for …

Replicating RNA, including self-amplifying RNA (saRNA) and trans-amplifying RNA
(taRNA), holds great potential for advancing the next generation of RNA-based vaccines …